122225-67-6Relevant articles and documents
Studies directed toward the design of orally active renin inhibitors. 1. Some factors influencing the absorption of small peptides
Rosenberg,Spina,Woods,Polakowski,Martin,Yao,Stein,Cohen,Barlow,Egan,Tricarico,Baker,Kleinert
, p. 449 - 459 (2007/10/02)
A systematic evaluation of structure-absorption relationships using a high throughput intraduodenal rat screening model has led to the delineation of a set of structural parameters that appear to govern bioavailability in a series of peptide-based renin inhibitors. Optimum structures, exemplified by 25 and 41, incorporated a single, solubilizing substituent at the C- or N- terminus combined with a lipophilic P2-site residue. Both inhibitors gave unprecedented plasma drug levels upon intraduodenal administration to monkeys, and the calculated bioavailability for 41 (14 ± 4%) is the highest reported for any peptidic renin inhibitor.
PEPTIDYL AMINODIOL RENIN INHIBITORS
-
, (2008/06/13)
A renin inhibiting compound having an aminodiol functional group is useful for treating hypertension, congestive heart failure and glaucoma and inhibits retroviral protease.
Renin-inhibiting functionalized peptidyl aminodiols and - triols
-
, (2008/06/13)
A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.
